{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:26:54Z","timestamp":1793370414168,"version":"4.5.0"},"reference-count":31,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370787"],"award-info":[{"award-number":["82370787"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Thyroid-stimulating immunoglobulin (TSI) and thyrotropin receptor antibody (TRAb) are specific biomarkers for Graves disease (GD), but their clinical characteristics are not fully understood.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To clarify the clinical features and prognostic significance of TSI and TRAb in patients with GD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective data analysis and a follow-up study. Medical records of patients newly diagnosed with GD were examined. TSI and TRAb correlations were assessed using Passing-Bablok regression and Bland-Altman plot. Patients were categorized into unresolved (Group A) and resolved (Group B) hyperthyroidism based on thyroid function after 1 month of therapy. The relationship between thyroid function and changes in TRAb and TSI was analyzed. Logistic regression identified relapse risk factors, including TSI levels at antithyroid drugs (ATDs) withdrawal in the follow-up study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Data from 957 patients (762 female and 195 male) revealed a strong correlation between TRAb and TSI (r = 0.873, P &amp;lt; .001). Compared to group B, group A showed minimal antibody decline (100% [interquartile range (IQR) 87.91%-115.1%] and 100% [IQR 85.03%-118.3%], respectively). Among 206 patients followed for over 12 months after ATD discontinuation, the relapse rate was 41.26%. Relapse was more frequent in patients with positive TSI (54.84% vs 35.42%, P &amp;lt; .05). Positive TSI levels at withdrawal, past history of GD, age, and mild thyroid-associated ophthalmopathy were independent relapse predictors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>TSI and TRAb are strongly correlated in GD, with slow antibody decline linked to unresolved hyperthyroidism. Discontinuing ATDs may be considered when both TSI and TRAb are negative.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgae892","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T14:38:09Z","timestamp":1734964689000},"page":"e3002-e3010","source":"Crossref","is-referenced-by-count":13,"title":["Significance of Thyroid-Stimulating Immunoglobulin and Thyrotropin Receptor Antibody in Graves Disease"],"prefix":"10.1210","volume":"110","author":[{"given":"Rongguang","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]},{"name":"Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0896-6269","authenticated-orcid":false,"given":"Pu","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]},{"name":"Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]},{"name":"Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]},{"name":"Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]},{"name":"Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]},{"name":"Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2573-5110","authenticated-orcid":false,"given":"Qinglei","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]},{"name":"Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3728-2833","authenticated-orcid":false,"given":"Liyun","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]},{"name":"Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyang","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]},{"name":"Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4064-4460","authenticated-orcid":false,"given":"Lei","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]},{"name":"Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5605-9624","authenticated-orcid":false,"given":"Yulin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]},{"name":"Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4241-3749","authenticated-orcid":false,"given":"Shu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]},{"name":"Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"issue":"16","key":"2025081215531341300_dgae892-B1","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"2025081215531341300_dgae892-B2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S2213-8587(14)70225-6","article-title":"Iodine deficiency and thyroid disorders","volume":"3","author":"Zimmermann","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10047","key":"2025081215531341300_dgae892-B3","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(16)00278-6","article-title":"Hyperthyroidism","volume":"388","author":"De Leo","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"2025081215531341300_dgae892-B4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-020-0184-y","article-title":"Graves\u2019 disease","volume":"6","author":"Davies","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"2025081215531341300_dgae892-B5","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1089\/1050725042451248","article-title":"A new assay for thyrotropin receptor autoantibodies","volume":"14","author":"Smith","year":"2004","journal-title":"Thyroid"},{"issue":"6","key":"2025081215531341300_dgae892-B6","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1210\/jc.2012-4309","article-title":"Clinical review: clinical utility of TSH receptor antibodies","volume":"98","author":"Barbesino","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025081215531341300_dgae892-B7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1515\/cclm-2016-0197","article-title":"Evaluation of the first fully automated immunoassay method for the measurement of stimulating TSH receptor autoantibodies in Graves\u2019 disease","volume":"55","author":"Tozzoli","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"2025081215531341300_dgae892-B8","doi-asserted-by":"crossref","unstructured":"Peng R, Xie P, Jin Z, et al \u00a02024. Supplemental data for: Significance of Thyroid Stimulating Immunoglobulin and Thyrotropin Receptor Antibody in Graves\u2019 Disease. figshare. doi:10.6084\/m9.figshare.28014719.","DOI":"10.1210\/clinem\/dgae892"},{"issue":"10","key":"2025081215531341300_dgae892-B9","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"issue":"1","key":"2025081215531341300_dgae892-B10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4158\/EP-2019-0363","article-title":"TSH receptor antibodies: relevance & utility","volume":"26","author":"Kahaly","year":"2020","journal-title":"Endocr Pract"},{"issue":"2","key":"2025081215531341300_dgae892-B11","doi-asserted-by":"crossref","first-page":"101744","DOI":"10.1016\/j.beem.2023.101744","article-title":"Bioassays for thyrotropin receptor autoantibodies","volume":"37","author":"Olivo","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"2025081215531341300_dgae892-B12","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1309\/AJCPZUT7CNUEU7OP","article-title":"Analytical performance and clinical utility of a bioassay for thyroid-stimulating immunoglobulins","volume":"139","author":"Leschik","year":"2013","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"2025081215531341300_dgae892-B13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000490384","article-title":"2018 European thyroid association guideline for the management of Graves\u2019 hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur Thyroid J"},{"issue":"6","key":"2025081215531341300_dgae892-B14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1055\/a-0914-0535","article-title":"Comparison of a bridge immunoassay with two bioassays for thyrotropin receptor antibody detection and differentiation","volume":"51","author":"Allelein","year":"2019","journal-title":"Horm Metab Res"},{"issue":"6","key":"2025081215531341300_dgae892-B15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/00365513.2019.1658216","article-title":"Analytical and clinical performance of newly developed immunoassay for detecting thyroid-stimulating immunoglobulin, the Immulite TSI assay","volume":"79","author":"Kim","year":"2019","journal-title":"Scand J Clin Lab Invest"},{"issue":"6","key":"2025081215531341300_dgae892-B16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2174\/1381612013397898","article-title":"The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review","volume":"7","author":"Volp\u00e9","year":"2001","journal-title":"Curr Pharm Des"},{"issue":"1","key":"2025081215531341300_dgae892-B17","first-page":"CD003420","article-title":"Antithyroid drug regimen for treating Graves\u2019 hyperthyroidism","volume":"2010","author":"Abraham","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2025081215531341300_dgae892-B18","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1530\/eje.0.1470583","article-title":"Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves\u2019 disease","volume":"147","author":"Nedrebo","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"2025081215531341300_dgae892-B19","first-page":"e22190","article-title":"Thyroid-stimulatory antibody as a predictive factor for Graves\u2019 disease relapse","volume":"14","author":"Da Silva Santos","year":"2022","journal-title":"Cureus"},{"issue":"2","key":"2025081215531341300_dgae892-B20","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3803\/EnM.2016.31.2.300","article-title":"Usefulness of measuring thyroid stimulating antibody at the time of antithyroid drug withdrawal for predicting relapse of Graves disease","volume":"31","author":"Kwon","year":"2016","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"4","key":"2025081215531341300_dgae892-B21","doi-asserted-by":"crossref","first-page":"e1006","DOI":"10.1210\/clinem\/dgz292","article-title":"Prospective trial of functional thyrotropin receptor antibodies in Graves disease","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025081215531341300_dgae892-B22","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11154-016-9386-8","article-title":"Relapse prediction in Graves\u00b4 disease: towards mathematical modeling of clinical, immune and genetic markers","volume":"17","author":"Langenstein","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"issue":"6","key":"2025081215531341300_dgae892-B23","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s40618-021-01730-1","article-title":"Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves\u2019 disease: a systematic scoping review","volume":"45","author":"Azizi","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2025081215531341300_dgae892-B24","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1210\/jc.2018-01738","article-title":"Age may influence the impact of TRAbs on thyroid function and relapse-risk in patients with Graves disease","volume":"104","author":"Bano","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025081215531341300_dgae892-B25","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1210\/edrv-16-6-686","article-title":"The aging thyroid","volume":"16","author":"Mariotti","year":"1995","journal-title":"Endocr Rev"},{"issue":"1","key":"2025081215531341300_dgae892-B26","doi-asserted-by":"crossref","first-page":"bvad157","DOI":"10.1210\/jendso\/bvad157","article-title":"Stress-induced Graves disease: spontaneous recovery after stress relief","volume":"8","author":"Willems","year":"2023","journal-title":"J Endocr Soc"},{"issue":"6","key":"2025081215531341300_dgae892-B27","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ando.2018.09.002","article-title":"Graves\u2019 disease: introduction, epidemiology, endogenous and environmental pathogenic factors","volume":"79","author":"W\u00e9meau","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"issue":"9","key":"2025081215531341300_dgae892-B28","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1210\/clinem\/dgab191","article-title":"High levels of thyroid hormone impair regulatory T cell function via reduced PD-1 expression","volume":"106","author":"Zhong","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"7418","key":"2025081215531341300_dgae892-B29","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0140-6736(65)92501-8","article-title":"Influence of iodine intake after treatment with antithyroid drugs","volume":"2","author":"Alexander","year":"1965","journal-title":"Lancet"},{"issue":"8","key":"2025081215531341300_dgae892-B30","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1089\/thy.2015.0613","article-title":"Iodine status and prevalence of thyroid disorders after introduction of mandatory universal salt iodization for 16 years in China: a cross-sectional study in 10 cities","volume":"26","author":"Shan","year":"2016","journal-title":"Thyroid"},{"issue":"4","key":"2025081215531341300_dgae892-B31","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2265.2007.02933.x","article-title":"Patients with severe Graves\u2019 ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission","volume":"67","author":"Eckstein","year":"2007","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae892\/61267457\/dgae892.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/9\/e3002\/61267457\/dgae892.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/9\/e3002\/61267457\/dgae892.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T19:53:23Z","timestamp":1755028403000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/9\/e3002\/7931643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,12,23]]},"published-print":{"date-parts":[[2025,8,7]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae892","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2024,12,23]]}}}